Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

How Does Health Literacy Affect the Patient Global Assessment?

Arthritis Care & Research  |  May 8, 2019

For RA patients, a low score on the patient global assessment of disease activity as measured by a visual analog scale (PGA-VAS) is necessary to confirm remission. However, limited patient health literacy combined with the complexity of the scale may result in discrepancies between the PGA-VAS and provider assessments of disease activity. New research examined the patient perspective on the PGA-VAS and its connections to health literacy and disease state…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis Care & Researchhealth literacypatient global assessmentRheumatoid Arthritis (RA)

U.S. Government Website for Comparing Doctors Lacks Data

Lisa Rapaport  |  May 8, 2019

(Reuters Health)—Physician Compare, a U.S. website created to help patients find high-quality doctors, is missing so much information on individual providers that it may not be helpful, a new study suggests. Quality reporting has been a work in progress for almost three decades since a landmark 1999 report from the Institute of Medicine, ‘To Err…

Filed under:Professional Topics Tagged with:Centers for Medicare & Medicaid Services (CMS)decision-makingpatientphysicianPhysician Compare

New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

Kelly Tyrrell  |  May 8, 2019

As soon as pediatric patients are diagnosed with juvenile idiopathic arthritis (JIA), they should also be screened for uveitis, says ophthalmologist Gary Holland, MD. Otherwise, the University of California, Los Angeles, provider says, “Kids who are diagnosed with JIA may not come to an ophthalmologist until they have vision-limiting complications.” Uveitis is the most common…

Filed under:Clinical Criteria/GuidelinesConditionsOther Rheumatic Conditions Tagged with:JIA-associated uveitis guidelinejuvenile idiopathic arthritis (JIA)Uveitis

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

Michele B. Kaufman, PharmD, BCGP  |  May 7, 2019

Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…

Filed under:Biologics/DMARDsDrug Updates Tagged with:breastfeedingCanadaCertolizumab PegolNICEplaque psoriasispregnant womenU.K.

Characterization of Autoreactive B Cells in Patients with SLE & RA

Lara C. Pullen, PhD  |  May 6, 2019

Antibody-secreting cells are important for the pathophysiology of SLE and RA, but researchers have been unable to determine how these cells are activated. A new technique is able to distinguish between naïve autoreactive B cells and established antibody secreting cells…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:autoreactive B cellsRheumatoid Arthritis (RA)systemic lupus erythematosus (SLE)

ACR Leaders to Meet with Members of Congress

From the College  |  May 2, 2019

On May 16, ACR and ARP leaders serving on the Board of Directors, Affiliate Society Council, Government Affairs Committee, Committee on Rheumatologic Care, RheumPAC and Insurance Subcommittee will go to Capitol Hill to advocate on behalf of the College’s membership and our patients. The group represents 31 states and the District of Columbia, and will…

Filed under:ConditionsFrom the CollegeLegislation & AdvocacyOsteoarthritis and Bone DisordersWorkforce Tagged with:Capitol Hill fly-inDepartment of Defense (DoD)Ensuring Seniors’ Timely Access to Care Act of 2019Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act (S. 283)OsteoporosisSafe Step Act of 2019 (H.R. 2279)Strengthening our Pediatric Workforce Act (H.R. 1656)

Patients Value Convenience of Telemedicine

Lisa Rapaport  |  April 30, 2019

(Reuters Health)—Patients who have real-time video visits with their primary care providers instead of in-person exams are generally satisfied with the convenience and quality of their checkups, a new study suggests. There’s a lot about these telemedicine visits that can sound appealing: no need to get stuck in traffic on the way to the doctor;…

Filed under:Technology Tagged with:patient carepatient perspectivetelemedicinevideo-based telemedicine

FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2019

Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…

Filed under:Drug Updates Tagged with:axial spondyloarthritis (SpA)Certolizumab PegolFDAnon-radiographic axial spondyloarthritisU.S. Food and Drug Administration (FDA)

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

Megan Brooks  |  April 25, 2019

NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:alendronatedenosumabFracturesOsteoporosisosteoporosis treatmentsosteoporotic fracture rates

FDA Approves New Osteoporosis Medication

Michele B. Kaufman, PharmD, BCGP  |  April 23, 2019

Romosozumab-aqqg has been approved in the U.S. for treating postmenopausal women with osteoporosis at high risk of fracture…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAOsteoporosisosteoporosis treatmentspostmenopausalpostmenopausal womenromosozumab-aqqgU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 127
  • 128
  • 129
  • 130
  • 131
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences